Elmind Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Elmind Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$2.01M	–	36
2026 Q1	$2.01M	Hold	50,000	–	–	0.57%	27
2025 Q4	$1.26M	Buy	+50,000	New	+$1.17M	0.37%	32

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Elmind Capital's APLS Position: Q2 2026 in Review

Elmind Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 50,000 shares — an estimated $2.01M sold.

Elmind Capital first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $2.01M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Elmind Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Elmind Capital sold 50,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
Elmind Capital first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Elmind Capital's Apellis Pharmaceuticals position peaked at $2.01M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.